Endocrinology and diabetes services in the hospital outpatient setting are seeing the impact of introducing newer diabetes technologies for the care of children and adults with T1D on sensor‐augmented continuous subcutaneous insulin infusion (CSII) pumps and hybrid closed‐loop (HCL) automated insulin delivery (AID) devices. This evidence concerns the gene INS and diabetes mellitus.